In cellular models of Parkinson’s disease with PRKN mutations, this compound restores mitophagy to near-normal levels while enhancing ubiquitination markers (TOM20, SYNJ2BP) and phosphoubiquitin accumulation. This evidence concerns the gene TOMM20 and Parkinson disease.